|
FDA: Seizure risk from cefepime in patients with renal impairment. |
 |
 |
|
FDA: The U.S. Food and Drug Administration (FDA) is reminding health care professionals about the need to adjust the dosage of the antibacterial drug cefepime in patients with renal (kidney) impairment. There have been cases of a specific type of seizure called nonconvulsive status epilepticus associated with the use of cefepime, primarily in patients with renal impairment who did not receive appropriate dosage adjustments of cefepime. The Warnings and Precautions and Adverse Reactions sections of the cefepime label are being revised to highlight this risk.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
